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Influence of Tumor Characteristics on the Outcome of
Liver Transplantation Among Patients With Liver
Cirrhosis and Hepatocellular Carcinoma
J. Ignacio Herrero,* Bruno Sangro,* Jorge Quiroga,* Fernando Pardo,†
Maite Herraiz,* Javier A. Cienfuegos,† and Jesus Prieto*
Hepatocellular carcinoma (HCC) may recur after liver
transplantation (LT), mainly in patients with multinodu-
lar and large tumors. However, factors predictive of out-
come after LT in patients with small tumors remain ill
defined. We investigated which factors were related to
mortality or tumor recurrence among 47 liver transplant
recipients with liver cirrhosis and HCC and compared
them with 107 patients with liver cirrhosis without tumor
who underwent LT in the same period. Patients with HCC
were older (P < .001), more frequently had cirrhosis of a
viral origin (P < .001), and had lower Child-Pugh scores
(P < .001) than patients without tumor. Survival of
patients with and without tumor was not significantly
different (P 5 .20). Among patients with HCC, those with
lower recurrence-free survival rates had liver cirrhosis of a
viral origin, vascular invasion, bilobar disease, and tumor-
node-metastasis (TNM) stage IV. At multivariate analysis,
the only factor associated with mortality or recurrence was
TNM stage IV (P 5 .02). Our results suggest that in
patients with HCC and TNM stage IV, LT might be
contraindicated. (Liver Transpl 2001;7:631-636.)
The role of liver transplantation (LT) in the treat-ment of hepatocellular carcinoma (HCC) has
evolved. In the early ages, LT was indicated in all cases
of unresectable HCC without known extrahepatic
spread.1,2 Long-term survival was poor among patients
with advanced disease because of a high incidence of
tumor recurrence.3 In the 1990s, several series showed
that early HCC seldom recurred after LT and survival
was similar in patients with cirrhosis with or without
HCC.2,4-6 Some prefer LT over resection in these
patients.2,6-8
Several studies investigated which factors predispose
to HCC recurrence after LT. Several investigators stud-
ied which factors are related to post-LT outcome.2,5,8-11
Llovet et al5 did not find any factor predictive of
post-LT outcome. In other series, poor differentiation,
vascular invasion, greater number of tumor nodules,
and greater tumor size were related to lower survival or
disease-free survival rates,2,8,9,11 but most series were
based on unselected groups of patients and included a
considerable proportion of patients with large nodules.
The present study investigates factors associated
with mortality and tumor recurrence among 47
patients with HCC who underwent LT according to
well-defined selection criteria in a single center.
Patients and Methods
Between 1991 and June 2000 in our center, 160 adult
patients with liver cirrhosis underwent a first LT. Forty-seven
of these patients also had HCC diagnosed before LT, 6
patients had incidental HCC, and 107 patients had liver
cirrhosis without HCC. Patients with incidental HCC were
excluded from this retrospective study.
Patients with HCC were selected for LT if they had a
single nodule not exceeding 60 mm in diameter or 2 or 3
tumors, none exceeding 50 mm in diameter, assessed by com-
puted tomographic (CT) scan. Patients in whom vascular
invasion or extrahepatic spread was evident preoperatively
were excluded. LT was considered the treatment of choice for
all patients with HCC if they fulfilled these criteria and did
not have a contraindication for LT. Patients with HCC did
not have a priority for LT compared to other patients with
cirrhosis. During this period, only 2 patients were excluded
from the LT waiting list 6 and 7 months after their listing
because of progressing HCC.
As well as ultrasonography and CT scan, hepatic angiog-
raphy was generally performed before LT. When HCC had
been detected or suspected and it was technically feasible,
hepatic angiography was followed by selective transarterial
chemoembolization and lipiodol injection into both hepatic
lobes. A postlipiodol CT scan was repeated 2 to 3 weeks later
if the patient had not undergone LT by that time. If hepatic
angiography had been performed before referral for LT,
transarterial chemoembolization was performed only if the
expected waiting period before LT was longer than 3 months.
Preoperative staging of HCC included CT scan in all 47 cases,
ultrasound in 45 cases, hepatic angiography in 43 cases, and
postlipiodol CT scan in 37 cases. Extrahepatic spread was
From the * Liver Unit and † Department of Surgery, Clı´nica Uni-
versitaria, Pamplona, Spain.
Address reprint requests to J. Ignacio Herrero, MD, Liver Unit,
Clı´nica Universitaria, Av Pı´o XII S/N, 31008 Pamplona, Spain. Tele-
phone: 134-948-296-789; FAX: 134-948-296-500; E-mail:
iherrero@unav.es
Copyright © 2001 by the American Association for the Study of
Liver Diseases
1527-6465/01/0707-0010$35.00/0
doi:10.1053/jlts.2001.25458
631Liver Transplantation, Vol 7, No 7 ( July), 2001: pp 631-636
ruled out by bone scintigraphy, thoracic and abdominal CT
scan, and brain magnetic resonance imaging.
Two patients had an HCC resected 1 and 8 years previ-
ously and underwent LT because of tumor recurrence.
Thirty-two patients were treated while on the waiting list by
either percutaneous ethanol injection (5 patients) radiofre-
quency ablation (3 patients), or transarterial chemoemboliza-
tion (24 patients).
Fine-needle aspiration biopsy was performed in 18
patients, resulting in the diagnosis of HCC in 12 patients. In
the remaining 6 patients, LT was indicated despite a cytolog-
ical specimen negative for malignancy because the diagnosis
of HCC was highly probable on the basis of imaging tech-
niques. In 5 of these 6 patients, pathological examination of
the liver confirmed the diagnosis of HCC (in 1 patient, com-
plete necrosis of the nodule was observed after transarterial
chemoembolization). In another 29 patients, preoperative
diagnoses of HCC were based on radiological examination.
Pathological examination of the liver confirmed the diagnosis
in 24 patients (in 5 patients with single nodules, preoperative
treatment achieved total necrosis of the tumor).
The number, site, and size of all tumor nodules found in
the explanted liver, histological differentiation grade accord-
ing to criteria of Edmonson and Steiner,12 and the presence of
vascular invasion were obtained from pathological records.
The presence of tumor capsule was not considered for analysis
because preoperative treatment achieved complete necrosis in
11 of the patients with solitary nodules.
Immunosuppressive therapy consisted of cyclosporine or
tacrolimus, azathioprine, and prednisone. Patients who
underwent LT for chronic hepatitis B virus infection were
administered prophylaxis with intravenous hepatitis B
immune globulin. Patients with a postoperative diagnosis of
vascular invasion and/or more than 10 tumor nodules were
considered for adjuvant chemotherapy with doxorubicin
(60 mg/m2 intravenously, every 4 weeks for 4 cycles) starting
within the first postoperative month after serum bilirubin
levels were less than 3 mg/dL. The 3 patients with more than
10 tumor nodules and 7 of 9 patients with vascular invasion
underwent such therapy. In 2 patients, chemotherapy was not
started because of postoperative complications.
Screening for tumor recurrence was by measurements of
alphafetoprotein, abdominal ultrasound, and chest radio-
graph every 6 months and when clinically indicated. Diagno-
sis of HCC recurrence was based on pathological examination
in all cases.
Patients were followed up until February 20, 2000, a fol-
low-up for survivors of at least 8 months.
Statistical Analysis
Epidemiological and laboratory values are expressed as mean
and interquartile range. Length of follow-up is shown as
median and range.
Patients with HCC diagnosed before LT and patients
without HCC were compared for age, sex, Child-Pugh sta-
tus,13 cause of liver cirrhosis (viral v nonviral), and time on the
waiting list before LT by using 2-tailed Student’s t-test for
continuous variables and Chi-squared test and Fisher’s exact
test, as appropriate, for categorical variables. Kaplan-Meier
method was used to obtain actuarial survival rates, and both
curves were compared using the log-rank test.
The influence on recurrence-free survival of the following
variables was assessed: age (.60 v ,60 years), sex, viral liver
disease, biopsy of the tumor before LT, Child’s class (A versus
B or C), Okuda’s stage14 (I or II v III), Cancer of the Liver
Italian Program stage15 (0 or 1 v $2), Barcelona Clinic Liver
Cancer stage16 (A v B, C, or D), alphafetoprotein level (.10
v ,10 ng/mL and .100 v ,100 ng/mL), preoperative tumor
treatment, graft rejection, and pathological characteristics of
the tumor, including number of tumor nodules (solitary v
multinodular and 1 to 3 v .3 nodules); tumor diameter (.30
v #30 mm and .40 v #40 mm); unilobar or bilobar tumor;
pathological tumor-node-metastasis (pTNM) stage17 (stage I,
II, or III v IV); vascular invasion, and degree of differentiation
(Edmonson’s grade I or II v III). Statistical significance of
Kaplan-Meier estimates was analyzed by log-rank test, and
variables with P less than .05 were entered in a multivariate
Cox model. Multivariate Cox proportional hazard regression
models were performed to estimate the adjusted ratios for risk
factors of mortality and tumor recurrence.
Results
Basal characteristics of patients with and without HCC
are listed in Table 1. Patients with HCC were older and
had better liver function than patients without HCC,
and their liver disease was more frequently of viral ori-
gin.
Ten patients in the HCC group and 15 patients in
the non-HCC group died after a median follow-up of
33 months (range, 2 to 116 months) and 51 months
(range, 0 to 119 months), respectively. Cause and time
of death of patients in both groups are listed in Table 2.
Main causes of death in both groups were infectious
diseases. Two patients died of tumor recurrence 7 and 9
months after LT. Actuarial survival (Fig. 1) was not
significantly different between the groups.
Clinical staging and main radiological and patholog-
ical tumor characteristics are listed in Table 3.
Accuracy of Liver Imaging
CT staging was compared with pathological findings.
Radiological assessment had a trend to underestimate
the number of tumor nodules; 14 of 31 patients (45%)
with solitary HCC assessed by imaging techniques were
found to bear additional nodules. Radiological TNM
staging underestimated pTNM in 23 cases (49%) and
overestimated it in 2 cases (4%). The upgrade of
pTNM staging was caused by the detection of vascular
invasion in the liver explant in 4 cases.
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Recurrence
Tumor recurred in 6 patients at 5, 9, 16, 17, 32, and 33
months after LT. Sites of recurrence were lung (5 cases),
liver (2 cases), bone (1 case), chest wall (1 case), and
lymph nodes (1 case). Patients’ main baseline charac-
teristics are listed in Table 4. Two patients died of
tumor recurrence 7 and 9 months after LT, another
patient with tumor recurrence died of an unrelated
cause (biliary complications secondary to hepatic artery
thrombosis) 18 months after LT, and 3 patients are
currently alive 42, 50, and 63 months after LT. Figure
2 shows the actuarial recurrence-free survival curve.
Analysis of Factors Predictive of Disease-Free
Survival
Table 5 lists 1-, 2-, and 3-year actuarial disease-free
survival rates in the HCC group for those variables
reaching significance in univariate analysis. Patients
with viral liver disease, bilobar tumor, pTNM stage IV,
and microscopic vascular invasion had poorer disease-
free survival than patients with nonviral liver disease;
unilobar HCC; pTNM stages I, II or III; and without
microscopic vascular invasion. In multivariate analysis,
the only factor independently associated with mortality
or recurrence was pTNM stage IV compared with
stages I, II, and III (adjusted relative risk, 3.91; 95%
confidence interval, 1.26 to 12.13; P 5 .02).
Discussion
Results of the present study confirm that selected
patients with liver cirrhosis and HCC may undergo LT
with excellent results. In our center, LT was considered
in patients with solitary HCC with a maximum diam-
eter of 60 mm and those with 2 or 3 nodules up to 50
Table 2. Causes of Death for Patients With and
Without HCC
HCC N Without HCC N
Infections 3 Infections 8
Tumor recurrence 2 De novo neoplasia 3
Recurrent hepatitis B 1 Postoperative
bleeding
1
Bleeding after liver
biopsy
1 Central myelinolysis 1
Biliary complications 1 Cerebral hemorrhage 1
Sudden death 1 Chronic renal failure 1
De novo neoplasia 1 Biliary complications 1
Figure 1. Actuarial patient survival after orthotopic LT in
47 patients with HCC diagnosed before LT and 107
patients with liver cirrhosis without HCC.
Table 1. General Characteristics of Patients With and Without HCC
HCC (n 5 47) Without HCC (n 5 107) P
Sex (men/women) 37/10 76/31 NS
Age (yr) 60.74 (55-67) 53.57 (48-62) ,.001
Cause of cirrhosis
Viral 31 (66%) 32 (30%) ,.001
Hepatitis C virus 28 (60%) 27 (25%)
Alcoholic 12 (26%) 47 (44%)
Others 4 (8%) 28 (26%)
Child’s class ,.001
A 15 (30%) 3 (3%)
B 22 (49%) 56 (52%)
C 10 (21%) 48 (45%)
Child-Pugh score 7.91 (6-9) 9.48 (8-11) ,.001
Time waiting for LT (d) 117.28 (20-209) 118.05 (25-193) NS
Abbreviation: NS, not significant.
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mm. Using these selection criteria, survival rates of
patients with and without HCC were similar. One-, 3-,
and 5-year survival estimates for patients with HCC
were 87%, 79%, and 79%, and 1-, 2-, and 3-year actu-
arial recurrence-free survival rates rates were 87%, 82%,
and 70%, respectively. These results are similar to those
of previous series of liver transplant recipients with
HCC at an early stage.2,4-6
In previous reports of selected series of LT recipients
with HCC, Mazzaferro et al4 found that survival was
higher in patients with correct preoperative staging
within their inclusion criteria than in patients with
more advanced disease, and Figueras et al6 found that
patients with tumor nodules greater than 5 cm and
macroscopic vascular invasion had a greater mortality
rate. Conversely, Llovet et al5 did not find a correlation
between tumor characteristics and patient outcome,
but in this series, 12% of the patients had incidental
HCC. In our study, patients with cirrhosis of viral
origin, microscopic vascular invasion, bilobar disease,
and pTNM stage IV did worse than patients with non-
Table 3. Tumor Characteristics of 47 Liver Transplant
Recipients With HCC
Alphafetoprotein (,10/10-100/.100
ng/mL) 29/11/6
Clinical staging
Okuda (I/II/III) 15/22/10
CLIP (0/1/2/.2) 6/16/19/6
BCLC (A/B/C/D) 24/11/1/11
Radiological staging (CT scan)
No. of nodules (0/1/2/3) 4/31/7/5*
Maximum diameter (mm) (n 5 43)† 33.07 (20-40)
1-30 27
31-40 7
41-50 4
.50 5
Lobar involvement (unilobar/bilobar) 37/6
TNM (0/I/II/III/IV) 4/7/24/6/6
Pathological staging
No. of nodules (1/2/3/.3) 21/8/6/12
Maximum diameter (mm) 31.47 (22-36)
1-30 26
31-40 13
41-50 6
51-60 2
Lobar involvement (unilobar/bilobar) 34/13
TNM (I/II/III/IV) 4/15/14/14
Microscopic vascular invasion 9‡ (17%)
Differentiation degree§ (I/II/III) 6/15/19
Abbreviations: CLIP, Cancer of the Liver Italian Program;
BCLC, Barcelona Clinic Liver Cancer.
* Four cases were detected by computed tomography (CT),
but were detected preoperatively by ultrasonography (3 cases)
and hepatic angiography (4 cases).
† Patients with tumors not detected on CT scan were not
included.
‡ Two patients also had macroscopic vascular invasion.
§ Not available in 7 patients because of complete necrosis.
Table 4. Baseline Characteristics of 6 Patients With Recurrent HCC After LT
Age (yr) 67 68 64 61 73 68
Sex Female Female Male Male Male Male
Cause of cirrhosis Hepatitis C Hepatitis C Hepatitis C Hepatitis C Alcohol Hepatitis C
Waiting time (d) 14 226 52 63 255 22
Alphafetoprotein (ng/mL) 1,900 11 198 1 6 6
No. of tumors 1 3 2 6 .10 2
Vascular invasion Yes Yes Yes Yes No No
pTNM IV III IV IV IV III
Differentiation grade III III III III III III
Preoperative treatment TAE No No No TAE TAE
Postoperative treatment Yes Yes Yes Yes Yes No
Abbreviation: TAE, transarterial chemoembolization.
Figure 2. Actuarial survival free of tumor recurrence after
orthotopic LT in 47 patients with HCC.
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viral cirrhosis, no vascular invasion, unilobar disease, or
pTNM stages I to III. The only factor independently
predictive of recurrence or mortality was pTNM stage
IV, suggesting that LT should be questioned in patients
with HCC and pTNM stage IV, as suggested in series of
unselected liver transplant recipients with HCC.
Unfortunately, only 6 of 14 patients (43%) with
pTNM stage IV were correctly staged on a CT basis,
and when the worst stage of a combination of imaging
techniques was used, only 8 of 14 patients (57%) were
correctly identified. Conversely, no patient was misdi-
agnosed as TNM stage IV on a CT basis. The use of
iodized-oil CT scan has been reported to be very useful
in the preoperative staging of HCC, with an agreement
of 96% between radiological and pathological stag-
ing,18 but in the present series, such agreement was not
found.
The possible role of adjuvant chemotherapy in this
group of patients with a high risk for tumor recurrence
remains unclear. Encouraging results have been
obtained with the use of doxorubicin19 and the combi-
nation of doxorubicin and cisplatin.20 In our series,
postoperative doxorubicin was administered to patients
believed to have a high risk for tumor recurrence, but
half these patients had tumor recurrence. All but one of
the patients with HCC with recurrence had been
administered adjuvant chemotherapy. However, whether
adjuvant chemotherapy may have influenced the time to
recurrence in these patients could not be determined.
We could not ascertain whether pre-LT treatment
might reduce the risk for post-LT HCC recurrence.
Pre-LT treatment achieved complete tumor necrosis in
11 cases. None of them had post-LT recurrence. Con-
versely, only 1 of 15 patients with a single nonnecrotic
nodule had recurrence.
In summary, patients with small HCCs who
undergo LT have a survival similar to that of patients
with liver cirrhosis without HCC and an acceptable
recurrence-free survival rate. pTNM stage IV helps dis-
tinguish a subset of patients with a poor oucome, but
imaging techniques are not accurate enough to predict
pTNM stage because they miss a significant proportion
of patients with pTNM stage IV. Radiological TNM
stage IV might be considered a contraindication for LT.
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